This article refers to 'Machine learning-based phenogrouping in heart failure to identify responders to cardiac resynchronization therapy' by M. Cikes et al., published in this issue on pages 74-85.
We have come to rely on a high degree of speed, precision, and accuracy from the modern world. Algorithms can instantaneously map out all routes to our destination and adjust the path according to real-time traffic information; restaurant recommendations are transmitted to our devices as we walk through a neighbourhood relying on incredibly granular Global Positioning System (GPS) and personal preference data; millions of songs, books, and movies can be accessed on handheld devices with just a few clicks. However, in medicine, no less a data science than other field, the norm is uncertainty, imprecision, and inaccuracy. A rather dramatic illustration of this is the case of implantable cardioverter defibrillators (ICD) with the capacity for cardiac resynchronization therapy (CRT) -despite the expense and invasive nature of the therapy, our ability to predict who will benefit from it remains archaic and inexact. It is for this reason that a wide-ranging effort by a group from Europe and the United States that applies machine learning to improve prediction of CRT response and appears in this issue of the Journal is both timely and long awaited. 
Why is this study important and what did the authors find?
When CRT works in patients with heart failure, the results can be dramatic.
2 However, our current ability to predict responders depends on inexact variables such as New York Heart Association (NYHA) class, ejection fraction, and electrocardiographic (ECG) * characteristics, all of which fall far short of what is required for a definitive clinical recommendation for the individual patient. As a result, current guidelines are focused around the principal inclusion and exclusion criteria of clinical trials, with an acknowledgement that one in three patients will be non-responders. 3 The authors of the manuscript we are editorializing used data from the landmark Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) trial that demonstrated whether CRT with a defibrillator (CRT-D) had benefit over ICD alone in patients with mild heart failure, left ventricular ejection fraction ≤ 30% and QRS duration ≥ 130 ms. 4 The trial was stopped early due to the efficacy of CRT-D. To examine whether the application of machine learning methodology to an extensive set of baseline variables from this trial might improve prediction of CRT response, the authors selected 50 variables that included demographic and laboratory data, as well as ECG and detailed echocardiography measures across the cardiac cycle and including global longitudinal strain (GLS). Next, they applied an 'unsupervised' machine learning methodology called multiple kernel learning to the dataset, labelled as such because it is agnostic with regard to the relationships between the data elements and groups patients according to distance between 'kernels' which comprise dissimilar data types. Four clusters, or 'phenogroups', appeared to yield the best partitioning of treatment effect and comprised the variables previously known to predict responder vs. non responder status. For example, phenogroups 1 and 3 included the highest proportion of patients with non-ischaemic cardiomyopathy, left bundle branch block, and females. On the other hand, phenogroups 2 and 4 included the highest proportion of male patients with ischaemic cardiomyopathy and a low proportion of patients with left bundle branch block. Additionally, the granular echocardiographic data allowed the investigators to associate clinical features with imaging 'fingerprints', giving them novel insights into the detailed structural predictors of CRT response, as well as examine its impact on remodelling. Two of the phenogroups showed dramatic responses to CRT, with an approximate 65% reduction in risk of heart failure events or death. Importantly, their analysis surpassed the predictive capabilities of clinical or echocardiographic parameters alone. The authors concluded that the path to clinical integration of these algorithms is fairly straight-forward as the clinical variables are collected as part of usual care and the echo-based analyses can be programmed into echocardiographic post-processing equipment that already extracts the descriptors they used. However, this recommendation must be considered with the caveat that they used highly curated data from a randomized clinical trial and the algorithms need to be applied to routinely collected data to investigate their performance in clinical practice.
What are the implications of the study?
This study proves a concept that we have long presumed: applying sophisticated algorithms to a rich clinical dataset of heart failure patients getting CRT can extract previously unknown insights about disease phenotypes and response to therapy. 5, 6 However, it is essential that this effort not go from 'desktop to bookshelf' -indeed, large medical datasets and machine learning algorithms have been available for decades, and have yielded thousands of papers, but almost none have contributed meaningfully to clinical care. Rather, we must use this research to map out a route to the bedside. Below are some of the key obstructions we must traverse for this to occur.
We need more objective descriptors of heart failure
Complex decisions in heart failure such as whether a patient will benefit from resynchronization therapy rely on three key heart failure variables -NYHA class, left ventricular ejection fraction, and ECG characteristics -all of which have been in clinical use almost a century and are widely acknowledged to be inadequate descriptors of this complex syndrome. 7 Nonetheless, clinical trials, guidelines, and practice continues to be anchored in these variables, unable to be liberated by the constraints of tradition. Moving forward, there is a need to redefine the syndrome of heart failure from the ground up using more objective measures such as biomarkers and advanced imaging, as even the most sophisticated of analytic methodologies will be ineffective if anchored in imprecise classification schemata. To achieve this, large volumes of granular heart failure patient data are needed across different regions and standardized clinical settings, along with collaboration in regard to analytic methodologies.
. 
We need statistical 'best practices' and quality control for advanced analytics
There has been a logarithmic rise in the number of publications applying machine learning methodologies to clinical datasets. A PubMed query of the term yielded 469 publications in 2008 and 4621 in 2018. With this increase, the expectations of these approaches have moved beyond their innovative potential to where they must show a clear route to clinical implementation. 8 The method used in this manuscript is one of several data mining methods that could have been used for this purpose, and these subjective analytic choices can yield very different results. 9 Furthermore, as the authors admit in the Methods section, their choice of the number of clusters that form the bedrock for their findings was based on maximizing statistical significance, an approach that is self-serving and increases risk of type 1 error. As we work towards applying machine learning to clinical decision making, there is a need for clearer guidelines on the benefits and drawbacks of various approaches, as well as greater structure around choices like the appropriate number of clusters. We also need to ensure that the algorithms applied clinically follow the FACT principles (i.e. they are fair, accurate, confidential, and transparent), and are valid across patient groups often underrepresented in traditional clinical trials.
10 Finally, as a substantial usage of these algorithms in routine practice is expected in the near future, proper evaluation on the background of usual care is warranted using randomization; cluster randomization or stepped-wedge designs could be considered.
Research and clinical practice need greater integration
Although the academic medical centre arose from a tradition of bedside clinical research to improve care, this has evolved into an emphasis on reductionism that is contrary to the intricacies and complexity of illnesses.
11 Subsequently, a large proportion of medical researchers and clinicians exist in distinct silos whilst vast amounts of data collected on patients remains unused. As advanced analytic methods show their potency in other aspects of daily life, academic medical centres are realizing the potential for data-driven approaches to streamline and enhance health care, with the goal of creating a learning health care system.
12 This study provides a route to rapid clinical integration whereby the algorithms developed by the investigators can be integrated into the electronic health record and provide instantaneous feedback about the probability of benefit from CRT; these can improve over time with ongoing collection of granular patient data (Figure 1) . In this iteration of the future, clinical data are the engine for continuous improvement, and there is a team-based approach to health care decision making centred around the patient that includes physicians, pharmacists, molecular pathologists, and data scientists. Since the ultimate objective of both clinicians and medical researchers is to improve outcomes from disease, there is great potential for a realignment in their roles in this 'big data' iteration of the modern health care system. Figure 1 A paradigm for use of advanced analytics to predict response to cardiac resynchronization therapy (CRT). To bring precision medicine to heart failure patients needing CRT will require a rethinking of our fundamental approaches to the syndrome and be driven by advanced analytics, granular patient information, and continuous feedback. CRT-D, cardiac resynchronization therapy with defibrillator; ECG, electrocardiogram; EHR, electronic health record; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
Conclusions
Heart failure is a terrible affliction and decision making around invasive therapies like CRT only adds to the patient's anxiety. Therefore, it is unacceptable for us to make recommendations about CRT based on inaccurate and imprecise measures of heart failure, expecting that patients should be content with a two in three chance of feeling better. This work by Cikes and colleagues shows us a path towards a more intelligent health care system, where the use of advanced analytics can help fix modern medicine's problem of uncertainty, imprecision, and inaccuracy. 
